Research location
Palmerston North
New Zealand
Advertisement
Research activity in Palmerston North
New ZealandCureCurrent currently publishes aggregate city-level research activity for this location: 40 trials and 40 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Palmerston North
40 linked trials · page 1 of 1This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Evaluating the Occurrence of DKA in People With Type I DiabetesNCT07739342 · 2026-09-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerNCT04619797 · 2020-12-15 · 1 site observation
COMPLETED
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateNCT04136353 · 2020-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerNCT04191499 · 2020-01-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer ChemotherapyNCT03948477 · 2019-06-10 · 1 site observation
COMPLETED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19 · 1 site observation
TERMINATED
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast CancerNCT02889874 · 2017-08-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseNCT02540993 · 2015-09-17 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseNCT02545049 · 2015-09-17 · 1 site observation
COMPLETED
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerNCT02446444 · 2014-03-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyNCT02065791 · 2014-02-17 · 1 site observation
COMPLETED
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusNCT01989754 · 2014-01-16 · 1 site observation
COMPLETED
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerNCT01630733 · 2012-10-24 · 1 site observation
COMPLETED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation
TERMINATED
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesNCT01481116 · 2012-01-01 · 1 site observation
TERMINATED
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerNCT01358877 · 2011-11-08 · 1 site observation
COMPLETED
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate CancerNCT01234311 · 2011-03-01 · 1 site observation
COMPLETED
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusNCT01144338 · 2010-06-18 · 1 site observation
COMPLETED
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusNCT01042769 · 2010-02-01 · 1 site observation
COMPLETED
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational StudyNCT00949286 · 2010-01-01 · 1 site observation
COMPLETED
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)NCT00887380 · 2009-09-16 · 1 site observation
UNKNOWN
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeNCT00968708 · 2009-09-01 · 1 site observation
COMPLETED
Radiotherapy - Adjuvant Versus Early SalvageNCT00860652 · 2009-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusNCT00856284 · 2009-03-01 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerNCT00829166 · 2009-02-01 · 1 site observation
COMPLETED
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCNCT00806819 · 2008-12-01 · 1 site observation
COMPLETED
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerNCT00703326 · 2008-08-06 · 1 site observation
COMPLETED
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation
COMPLETED
A Trial of MitoQ for the Treatment of People With Parkinson's DiseaseNCT00329056 · 2006-05-01 · 1 site observation
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00949910 · 2004-11-01 · 1 site observation
COMPLETED
Androgen Deprivation Therapy in Treating Patients With Prostate CancerNCT00110162 · 2004-10-01 · 1 site observation
UNKNOWN
RADAR Trial - Randomised Androgen Deprivation and RadiotherapyNCT00193856 · 2003-10-01 · 1 site observation
COMPLETED
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesNCT00379769 · 2001-04-01 · 1 site observation
COMPLETED
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast CancerNCT00241449 · 1998-11-01 · 1 site observation
COMPLETED
Study of Abiraterone Acetate in Patients With Advanced Prostate CancerNCT01217697 · 1 site observation
APPROVED_FOR_MARKETING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.